Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vincristine Sulfate

FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vincristine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vincristine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

    NCT07649304 · start 2026-10-09

    Registered record
    Registry ID
    NCT07649304
    Conditions
    AIDS-Related Diffuse Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8; Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8; Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8; Plasmablastic Lymphoma; Primary Effusion Lymphoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Doxorubicin Hydrochloride; Echocardiography Test; Glofitamab; Positron Emission Tomography; Prednisone; Questionnaire Administration; Rituximab; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-09
    Completion
    2028-04-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS-Related Diffuse Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified +5 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy +10 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

    NCT07294677 · start 2026-03-17

    Registered record
    Registry ID
    NCT07294677
    Conditions
    Leukemia; Lymphoma
    Interventions
    Capivasertib; Venetoclax; Rituximab; Blinatumomab; Nelarabine; mini-hyperCVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-03-17
    Completion
    2032-03
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    InterventionCapivasertib; Venetoclax; Rituximab; Blinatumomab +2 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    NCT06124157 · start 2025-05-30

    Registered record
    Registry ID
    NCT06124157
    Conditions
    B Acute Lymphoblastic Leukemia
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-30
    Completion
    2030-12-01
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol +17 more
    PhasePhase 2
    Registry statusRecruiting

  • Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    NCT07152041 · start 2025-03-28

    Registered record
    Registry ID
    NCT07152041
    Conditions
    Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventions
    olverembatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2030-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventionolverembatinib
    PhasePhase 3
    Registry statusRecruiting

  • Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

    NCT05996185 · start 2024-10-09

    Registered record
    Registry ID
    NCT05996185
    Conditions
    T Cell Lymphoma; T-cell Lymphoma
    Interventions
    Mogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2027-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma; T-cell Lymphoma
    InterventionMogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    NCT06549595 · start 2024-08-07

    Registered record
    Registry ID
    NCT06549595
    Conditions
    Untreated Follicular Lymphoma
    Interventions
    Surovatamig; R-CHOP; R-CVP; BR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-07
    Completion
    2031-11-26
    Enrolment
    1,018

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUntreated Follicular Lymphoma
    InterventionSurovatamig; R-CHOP; R-CVP; BR
    PhasePhase 3
    Registry statusRecruiting

  • Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

    NCT05820841 · start 2023-06-07

    Registered record
    Registry ID
    NCT05820841
    Conditions
    Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    Interventions
    R-miniCHOP + Acalabrutinib; R-miniCHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-06-07
    Completion
    2029-02
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    InterventionR-miniCHOP + Acalabrutinib; R-miniCHOP
    PhasePhase 3
    Registry statusRecruiting

  • Venetoclax Basket Trial for High Risk Hematologic Malignancies

    NCT05292664 · start 2023-03-29

    Registered record
    Registry ID
    NCT05292664
    Conditions
    Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
    Interventions
    Venetoclax; Azacitidine; Cytarabine; Methotrexate; Hydrocortisone; Leucovorin; Dexamethasone; Vincristine; Doxorubicin; Dexrazoxane; Calaspargase Pegol; Erwinia asparaginase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-03-29
    Completion
    2030-07-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia +7 more
    InterventionVenetoclax; Azacitidine; Cytarabine; Methotrexate +8 more
    PhasePhase 1
    Registry statusRecruiting

  • Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors

    NCT05378256 · start 2022-01-10

    Registered record
    Registry ID
    NCT05378256
    Conditions
    Lymphoma; Peripheral Neuropathy
    Interventions
    Clinical scales of CIPN
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-01-10
    Completion
    2025-03-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Peripheral Neuropathy
    InterventionClinical scales of CIPN
    PhaseNot applicable
    Registry statusCompleted

  • A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

    NCT04702581 · start 2021-12-07

    Registered record
    Registry ID
    NCT04702581
    Conditions
    Oligodendroglioma; Low-grade Oligodendroglioma; 1p19q Codeletion
    Interventions
    PCV chemotherapy; Radiotherapy and PCV chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-12-07
    Completion
    2030-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOligodendroglioma; Low-grade Oligodendroglioma; 1p19q Codeletion
    InterventionPCV chemotherapy; Radiotherapy and PCV chemotherapy
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

    NCT05026229 · start 2021-09-06

    Registered record
    Registry ID
    NCT05026229
    Conditions
    Precursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia-Positive Acute Lymphoblastic Leukemia; ALL, Adult
    Interventions
    dasatinib plus consolidation chemotherapy with vincristine and prednisone; dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-09-06
    Completion
    2023-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia-Positive Acute Lymphoblastic Leukemia; ALL, Adult
    Interventiondasatinib plus consolidation chemotherapy with vincristine and prednisone; dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
    PhaseNot applicable
    Registry statusUnknown

  • Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

    NCT04692155 · start 2021-08-31

    Registered record
    Registry ID
    NCT04692155
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Ublituximab; Umbralisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-08-31
    Completion
    2022-06-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionUblituximab; Umbralisib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of N9 Chemotherapy in Children With Neuroblastoma

    NCT04947501 · start 2021-06-22

    Registered record
    Registry ID
    NCT04947501
    Conditions
    Neuroblastoma; Pediatric Cancer
    Interventions
    Cyclophosphamide; Topotecan; Vincristine; Doxorubicin; Ifosfamide; Etoposide; Carboplatin; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2021-06-22
    Completion
    2027-06-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Pediatric Cancer
    InterventionCyclophosphamide; Topotecan; Vincristine; Doxorubicin +4 more
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

    NCT05425654 · start 2021-05-17

    Registered record
    Registry ID
    NCT05425654
    Conditions
    Primary CNS Lymphoma
    Interventions
    Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05-17
    Completion
    2026-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary CNS Lymphoma
    InterventionRituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
    PhasePhase 2
    Registry statusUnknown

  • Split-Dose R-CHOP for Older Adults With DLBCL

    NCT03943901 · start 2021-02-17

    Registered record
    Registry ID
    NCT03943901
    Conditions
    Diffuse Large B Cell Lymphoma; DLBCL; Cancer
    Interventions
    Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-02-17
    Completion
    2027-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma; DLBCL; Cancer
    InterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +2 more
    PhasePhase 2
    Registry statusActive not recruiting